Comvita (CVT) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
17 Dec, 2025Opening remarks and agenda
Meeting opened with a traditional karakia, welcome, and housekeeping, emphasizing hybrid attendance and shareholder engagement.
Board and leadership team introduced, with apologies from some directors and advisors present.
Agenda included strategic reset, recapitalization, trading update, board priorities, operational and financial updates, formal business, voting on resolutions, Q&A, and general business.
Financial performance review
Inventory reduced by NZD 46.8 million in FY25 compared to FY24, with net debt down by NZD 17.4 million and further deleveraging expected.
NZD 12.6 million in cost reductions delivered in FY25, with full annualized savings in FY26 forecast.
Revenue and gross profit ahead of expectations, supported by improved distributor arrangements, club-retail volumes, and favorable currency movements.
FY26 outlook projects normalised EBIT (pre IFRS16) of $13.5m, with trading modestly ahead of forecast profitability.
Ongoing cost control and operational improvements are delivering benefits, with inventory reduction ahead of schedule.
Board and executive committee updates
Board chaired by Bridget Coates, with key committees led by independent directors.
New CEO and CFO appointed, bringing sector expertise and financial discipline; Karl Gradon as CEO in August 2025 and Mandy Tomkins-Dancey as CFO in October 2025.
Board strengthening its competencies, especially in FMCG, global markets, and operational excellence, with ongoing review of composition.
Leadership team expanded with new roles in science, marketing, people, and sustainability.
Latest events from Comvita
- Net profit $4.6m, revenue $118m, strong cash flow; North America drives growth, recapitalisation ongoing.CVT
H1 202623 Feb 2026 - Margin pressures, cost reduction, and strategic transformation drive the company's reset.CVT
AGM 20243 Feb 2026 - Revenue and profit fell sharply amid impairments and market contraction, with cost cuts in progress.CVT
H2 202423 Jan 2026 - Net loss of $6.5M, revenue down, but cash flow and inventory improved amid restructuring.CVT
H1 202524 Dec 2025 - Revenue down 4.1%, major loss from impairments, but cash flow and debt improved; 67% premium offer.CVT
H2 202523 Nov 2025